TKT Hopes To "Break Even" In 2006 Following Hunter Syndrome Therapy BLA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is "refocusing" on lysosomal storage disease therapies, with a BLA for Hunter syndrome agent I2S expected in 2005, CEO Astrue tells BIO.
You may also be interested in...
Shire/TKT Merger Deal Focuses On Dynepo Rights In Europe
Shire will promote TKT's Dynepo in Europe with part of its 200-person Fosrenol sales force. European rights to the erythropoietin product were one of the critical components to the $1.6 bil. acquisition. The deal also brings Shire two products in development.
Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal
Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.